A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal
women. Clinical evidence indicates potent antagonists of 5-HT2A are more likely to cause
hypothermia. Risperidone is a potent 5-HT2A and a dopamine D2 receptor antagonist and is
proposed to have effect on reduciton of hot flashes through its dopaminergic and serotonergic
antagonism. The primary purpose of this study is to determine if RCN3028 is effective and
safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with
the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot
flashes per day, or 50 per week at baseline.